Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

Alexander E. Perl, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Recher, Catherine C. Smith, Mark J. Levis, Stephen Strickland, Christoph Röllig, Marco Groß-Langenhoff, Wen-Chien Chou, Je-Hwan Lee, Hisayuki Yokoyama, Nahla Hasabou, Qiaoyang Lu, Ramon V. Tiu, Jessica K. Altman

Open source

DOI: 10.1038/s41408-022-00677-7
Published: 2022-05-30
Container: Blood Cancer Journal
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-022-00677-7,
  title = {Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib},
  author = {Alexander E. Perl and Naoko Hosono and Pau Montesinos and Nikolai Podoltsev and Giovanni Martinelli and Nicki Panoskaltsis and Christian Recher and Catherine C. Smith and Mark J. Levis and Stephen Strickland and Christoph Röllig and Marco Groß-Langenhoff and Wen-Chien Chou and Je-Hwan Lee and Hisayuki Yokoyama and Nahla Hasabou and Qiaoyang Lu and Ramon V. Tiu and Jessica K. Altman},
  year = {2022},
  journal = {Blood Cancer Journal},
  doi = {10.1038/s41408-022-00677-7},
  url = {https://doi.org/10.1038/s41408-022-00677-7}
}

RIS

TY  - JOUR
TI  - Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
AU  - Alexander E. Perl
AU  - Naoko Hosono
AU  - Pau Montesinos
AU  - Nikolai Podoltsev
AU  - Giovanni Martinelli
AU  - Nicki Panoskaltsis
AU  - Christian Recher
AU  - Catherine C. Smith
AU  - Mark J. Levis
AU  - Stephen Strickland
AU  - Christoph Röllig
AU  - Marco Groß-Langenhoff
AU  - Wen-Chien Chou
AU  - Je-Hwan Lee
AU  - Hisayuki Yokoyama
AU  - Nahla Hasabou
AU  - Qiaoyang Lu
AU  - Ramon V. Tiu
AU  - Jessica K. Altman
PY  - 2022
JO  - Blood Cancer Journal
DO  - 10.1038/s41408-022-00677-7
UR  - https://doi.org/10.1038/s41408-022-00677-7
ER  -

APA

Perl, A. E., Hosono, N., Montesinos, P., Podoltsev, N., Martinelli, G., Panoskaltsis, N., Recher, C., Smith, C. C., Levis, M. J., Strickland, S., Röllig, C., Groß-Langenhoff, M., Chou, W., Lee, J., Yokoyama, H., Hasabou, N., Lu, Q., Tiu, R. V., & Altman, J. K. (2022). Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer Journal. https://doi.org/10.1038/s41408-022-00677-7

Source records

crossref · retrieved 2026-09-25T22:52:41.747Z